Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 24.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 577,727 shares of the biopharmaceutical company’s stock after selling 184,961 shares during the quarter. Principal Financial Group Inc.’s holdings in Dynavax Technologies were worth $6,436,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DVAX. GAMMA Investing LLC grew its holdings in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the period. US Bancorp DE grew its stake in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter worth $45,000. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Dynavax Technologies during the 3rd quarter valued at $89,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Down 0.5 %

Shares of NASDAQ:DVAX opened at $12.77 on Thursday. The company has a 50 day moving average of $12.56 and a two-hundred day moving average of $11.56. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of 98.24 and a beta of 1.33.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.